Evidence map›Paper›PMID 30891136›Full record

ArticleACS medicinal chemistry letters2019

Lihai Yu, Nikola Despotovic, Michael S Kovacs, Christopher L Pin, Leonard G Luyt

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Can Nuclear Imaging Detect Trained Immunity in Cardiovascular Disease?Arteriosclerosis, thrombosis, and vascular biology · 2026
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lihai YuLondon Regional Cancer Program, 800 Commissioners Road East, London, Ontario N6A 5W9, Canada.
Nikola DespotovicDepartment of Physiology and Pharmacology, Medical Imaging, Medical Biophysics, Paediatrics, and Chemistry, The University of Western Ontario, London, Ontario N6A 3K7, Canada.
Michael S KovacsDepartment of Physiology and Pharmacology, Medical Imaging, Medical Biophysics, Paediatrics, and Chemistry, The University of Western Ontario, London, Ontario N6A 3K7, Canada.
Christopher L PinDepartment of Physiology and Pharmacology, Medical Imaging, Medical Biophysics, Paediatrics, and Chemistry, The University of Western Ontario, London, Ontario N6A 3K7, Canada.
Leonard G LuytLondon Regional Cancer Program, 800 Commissioners Road East, London, Ontario N6A 5W9, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The enzyme enhancer of zeste homologue 2 (EZH2) plays a catalytic role in histone methylation (H3K27me3), one of the epigenetic modifications that is dysregulated in cancer. The development of a positron emission tomography (PET) imaging agent targeting EZH2 has the potential to provide a method of stratifying patients for epigenetic therapies. In this study, we designed and synthesized a series of fluoroethyl analogs based upon the structure of EZH2 inhibitors UNC1999 and EPZ6438. Among the candidate compounds,

Identifiers

PMID30891136
PMCPMC6421531

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.